Clinical Trial

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

Study acronym: PHATHOM
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-02; most recent amendment 2026-02-11.
Status change: Not Yet Recruiting → Recruiting 2026-02-11
Trial Details
NCT Number NCT07053917
Lead Sponsor Johns Hopkins University
Collaborators: Rose Hill, Usona Institute, University of California, Berkeley
Conditions Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke +4 more
Enrollment 20 participants
Start Date 2026-02-09
Primary Completion 2027-02 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-13